Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rimegepant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL known ✓ | Q16602 | 20/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.51 |
| ▸ | CALCA | P06881 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimegepant SCHEMBL24131009 | 1.00 | CALCRL (1.00) | CALCRLADRB2CYP3A4RAMP1CALCA | |
| Rimegepant SCHEMBL29374210 | 1.00 | CALCRL (1.00) | CALCRLADRB2CYP3A4RAMP1CALCA | |
| Rimegepant SCHEMBL1670839 | 1.00 | CALCRL (1.00) | CALCRLADRB2CYP3A4RAMP1CALCA | |
| Rimegepant SCHEMBL2523699 | 1.00 | CALCRL (1.00) | CALCRLADRB2CYP3A4RAMP1CALCA | |
| Rimegepant SCHEMBL29592766 | 1.00 | CALCRL (1.00) | CALCRLADRB2CYP3A4RAMP1CALCA | |
| SCHEMBL30721761 | 0.97 | CALCRL (0.94) | CALCRLADRB2CYP3A4 | |
| Rimegepant SCHEMBL30563158 | 0.97 | CALCRL (0.94) | CALCRLADRB2CYP3A4 | |
| Rimegepant SCHEMBL29413909 | 0.96 | CALCRL (0.93) | CALCRLADRB2CYP3A4 | |
| Rimegepant SCHEMBL30064030 | 0.96 | CALCRL (0.93) | CALCRLADRB2CYP3A4 | |
| SCHEMBL30721794 | 0.96 | CALCRL (0.92) | CALCRLADRB2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023064195-A1 | CGRP ANTAGONISTS FOR TREATING TRIGEMINAL NEURALGIA | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-04-20 | — | — | WO | claimed |
| WO-2023034467-A2 | CGRP ANTAGONISTS FOR TREATING SKIN CONDITIONS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-03-09 | — | — | WO | claimed |
| WO-2023034466-A1 | CGRP ANTAGONISTS FOR TREATING PSORIASIS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-03-09 | — | — | WO | claimed |
| EP-2488512-B1 | CGRP receptor antagonists | BRISTOL MYERS SQUIBB CO (US) | 2013-11-27 | — | — | EP | claimed |
| US-8314117-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-20 | — | — | US | claimed |
| EP-2488512-A1 | CGRP RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2012-08-22 | — | — | EP | claimed |
| US-20110251223-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-13 | — | — | US | claimed |
| WO-2011046997-A1 | CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | claimed |
| EP-4631944-A2 | RIMEGEPANT FOR CGRP RELATED DISORDERS | Pfizer Ireland Pharmaceuticals Unlimited Company (IE) | 2025-10-15 | — | — | EP | disclosed |
| US-20240366618-A1 | CGRP Antagonists for Treating Trigeminal Neuralgia | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-11-07 | — | — | US | disclosed |
| US-20240358695-A1 | Pharmaceutical Compositions of Rimegepant | AUROBINDO PHARMA LTD (IN) | 2024-10-31 | — | — | US | disclosed |
| US-12030868-B2 | Prodrugs of CGRP antagonists | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-07-09 | — | — | US | disclosed |
| US-20240066028-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-02-29 | — | — | US | disclosed |
| US-20240066028-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-02-29 | — | — | US | disclosed |
| US-20120245356-A1 | Process for the Preparation of Cycloheptapyridine CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-27 | — | — | US | disclosed |
| WO-2012050764-A1 | PROCESS FOR THE PREPARATION OF CYCLOHEPTAPYRIDINE CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20110251223-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-13 | — | — | US | disclosed |
| US-20110251223-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-13 | — | — | US | disclosed |
| US-20110251223-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-13 | — | — | US | disclosed |
| WO-2011046997-A1 | CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245356-A1 | Process for the Preparation of Cycloheptapyridine CGRP Receptor Antagonists | CALCRL, OPRL1, CALCR | CALCRL 1/4885ADRB2 140/4885CYP3A4 834/4885 |
| US-20240366618-A1 | CGRP Antagonists for Treating Trigeminal Neuralgia | OPRL1, CALCRL, CALCR | CALCRL 2/4885ADRB2 301/4885CYP3A4 4474/4885 |
| US-20240358695-A1 | Pharmaceutical Compositions of Rimegepant | HTR3E, HTR5A, HRH4 | CALCRL 1293/4885ADRB2 293/4885CYP3A4 176/4885 |
| US-20240066028-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | CALCB, CALCA, CALCRL | CALCRL 3/4885ADRB2 1058/4885CYP3A4 4064/4885 |
| US-12030868-B2 | Prodrugs of CGRP antagonists | CALCRL, CALCA, CALCB | CALCRL 1/4885ADRB2 369/4885CYP3A4 1440/4885 |
| US-20110251223-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | CALCRL 1/4885ADRB2 44/4885CYP3A4 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.